Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 18/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 17/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21367135 | 1.00 | PRMT5 (0.41) | PRMT5WDR77ADORA3ADORA1RAPGEF3 | |
| SCHEMBL24489756 | 1.00 | PRMT5 (0.41) | PRMT5WDR77ADORA3ADORA1RAPGEF3 | |
| SCHEMBL21367292 | 1.00 | PRMT5 (0.41) | PRMT5WDR77ADORA3ADORA1RAPGEF3 | |
| SCHEMBL21356309 | 1.00 | PRMT5 (0.41) | PRMT5WDR77ADORA3ADORA1RAPGEF3 | |
| SCHEMBL21367163 | 1.00 | PRMT5 (0.41) | PRMT5WDR77ADORA3ADORA1RAPGEF3 | |
| SCHEMBL18009869 | 0.90 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL18009711 | 0.86 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL18009766 | 0.85 | PRMT5 (0.43) | PRMT5WDR77RAPGEF3 | |
| SCHEMBL7680471 | 0.84 | PI4KA (0.46) | PRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL6572792 | 0.84 | PI4KA (0.46) | PRMT5WDR77ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-11-04 | — | — | US | disclosed |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-3765461-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3765461-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2023-06-08 | — | — | US | disclosed |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2023-06-08 | — | — | US | disclosed |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2023-06-08 | — | — | US | disclosed |
| WO-2018160855-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-3292128-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS | Eli Lilly and Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-9840532-B2 | 5′-substituted nucleoside compounds | ELI LILLY AND COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840532-B2 | 5′-substituted nucleoside compounds | ELI LILLY AND COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840532-B2 | 5′-substituted nucleoside compounds | ELI LILLY AND COMPANY (US) | 2017-12-12 | — | — | US | disclosed |
| WO-2016178870-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS | ELI LILLY AND COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | ELI LILLY AND COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | ELI LILLY AND COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | ELI LILLY AND COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PRMT5 1552/4885WDR77 2124/4885ADORA3 1149/4885 |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | PRMT5 1097/4885WDR77 4003/4885ADORA3 1346/4885 |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | PRMT5 1426/4885WDR77 2978/4885ADORA3 1476/4885 |
| US-12459950-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 87/4885ADORA3 4439/4885 |
| US-20160326208-A1 | 5'-SUBSTITUTED NUCLEOSIDE COMPOUNDS | NT5C3B, MCL1, NSUN2 | PRMT5 74/4885WDR77 746/4885ADORA3 254/4885 |
| US-12440506-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 57/4885ADORA3 4372/4885 |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 112/4885ADORA3 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.